Your browser is no longer supported. Please, upgrade your browser.
Johnson & Johnson
IndexDJIA S&P500 P/E17.98 EPS (ttm)5.70 Insider Own0.01% Shs Outstand2.80B Perf Week2.24%
Market Cap286.94B Forward P/E15.74 EPS next Y6.51 Insider Trans-1.73% Shs Float2.80B Perf Month1.73%
Income16.32B PEG3.09 EPS next Q1.52 Inst Own66.90% Short Float0.93% Perf Quarter-3.26%
Sales74.33B P/S3.86 EPS this Y18.50% Inst Trans-0.76% Short Ratio2.83 Perf Half Y0.66%
Book/sh26.92 P/B3.81 EPS next Y5.22% ROA15.80% Target Price109.14 Perf Year15.30%
Cash/sh11.79 P/C8.69 EPS next 5Y5.82% ROE27.60% 52W Range88.32 - 108.23 Perf YTD-1.28%
Dividend2.80 P/FCF- EPS past 5Y5.30% ROI17.70% 52W High-5.29% Beta0.56
Dividend %2.73% Quick Ratio2.20 Sales past 5Y3.70% Gross Margin69.40% 52W Low16.07% ATR1.49
Employees128100 Current Ratio2.60 Sales Q/Q-0.60% Oper. Margin32.80% RSI (14)56.49 Volatility1.18% 1.48%
OptionableYes Debt/Eq0.20 EPS Q/Q-27.60% Profit Margin28.30% Rel Volume0.92 Prev Close102.80
ShortableYes LT Debt/Eq0.17 EarningsJan 20 BMO Payout37.00% Avg Volume9.16M Price102.51
Recom2.50 SMA202.25% SMA500.39% SMA2000.19% Volume8,462,071 Change-0.28%
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Apr-12-13Reiterated Deutsche Bank Buy $82 → $87
Mar-26-13Reiterated UBS Buy $81 → $87
Jan-11-13Reiterated UBS Buy $76 → $78
Jan-04-13Upgrade Deutsche Bank Hold → Buy $75 → $82
Nov-20-12Initiated Stifel Nicolaus Hold
Jul-18-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
Apr-18-12Reiterated UBS Buy $71 → $70
Dec-12-11Reiterated UBS Buy $72 → $69
Feb-27-15 12:10PM  Who Might Buy Puma Biotechnology? at
11:31AM  Cramer: Pharmacyclics-Johnson & Johnson Deal Unlikely at This Price at TheStreet
09:10AM  Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin at Forbes
08:04AM  Why should you invest in healthcare ETFs? Market Realist
07:00AM  Compelling Financial Benefit in Valeant's Latest Buy Morningstar
06:43AM  Decision on Ebola mass vaccination in August at earliest - WHO Reuters
05:42AM  Decision on widespread Ebola vaccination in August at earliest - WHO Reuters
Feb-26-15 07:08PM  10-K for Johnson & Johnson Company Spotlight
06:22PM  Cramer: 'I'm a happy camper'-Thanks, Europe! at CNBC
05:17PM  Idaho House panel endorses banning contact lens price floors AP
09:56AM  Medivation Tops Q4 Views On Strong Xtandi Results at Investor's Business Daily
09:00AM  Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Zacks
08:00AM  Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience PR Newswire
05:07AM  South Carolina court orders J&J to pay $136 mln in Risperdal case Reuters
Feb-25-15 03:31AM  Biosimilar copies of blockbuster drug launch in major EU markets Reuters
Feb-24-15 05:06PM  Big pharma diversifies business to mitigate patent risk Market Realist
04:52PM  Johnson & Johnson Loses Trial Over Risperdal And Male Breasts at The Wall Street Journal
02:27PM  Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That at Forbes
06:10AM  JOHNSON & JOHNSON Files SEC form 10-K, Annual Report EDGAR Online
Feb-23-15 04:03PM  Healthcare Breaks Out: More Upside Is Ahead at
01:57PM  3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis Benzinga
Feb-21-15 06:00AM  [video]'Mad Money' Lightning Round: J&J Must Get Its Game Back at TheStreet
Feb-20-15 07:00PM  Cramer: This stock is on a run CNBC
06:20PM  New conference focused on early-stage funding comes to Houston at American City Business Journals
12:28PM  What it takes to be called big pharma Market Realist
Feb-19-15 10:50AM  Boston Scientific Settles $7.2B J&J Suit for $600M, Stock Up - Analyst Blog Zacks
09:50AM  Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog Zacks
09:30AM  The Zacks Analyst Blog Highlights: TIAA-CREF Social Choice Equity Retail, Johnson & Johnson, Procter & Gamble, Domini Social Equity Investor and Apple - Press Releases Zacks
Feb-18-15 06:21PM  Can Boston Scientific Finally Move on From Its Guidant Mistake? at The Wall Street Journal
04:44PM  Boston Scientific Closes Up 12% Benzinga
02:42PM  Boston Scientific Soars 11% After Settling Dispute With Johnson & Johnson Benzinga
11:45AM  Social Responsible Investing Can Be Profitable Too: 2 Funds to Buy - Mutual Fund Commentary Zacks
10:59AM  Why Big Pharma Must Cure Its Bad Rap at Forbes
10:24AM  Sterne Agree Weighs In On Boston Scientific-Johnson & Johnson Litigation Settlement Benzinga
09:16AM  Stock Futures Show Mild Losses; Boston Scientific Bolts Higher at Investor's Business Daily
09:14AM  Boston Scientific (BSX) Stock Higher Today After Johnson & Johnson Suit Settlement at TheStreet
02:34AM  ITC Call Costs Jump as Stock Climbs to 2-Month High on Valuation at Bloomberg
12:56AM  PRESS DIGEST-New York Times business news - Feb 18 Reuters
12:12AM  Boston Scientific to Pay J&J $600 Million to Settle Guidant Suit at The Wall Street Journal
Feb-17-15 06:20PM  Boston Scientific will pay Johnson & Johnson $600M AP
05:40PM  Boston Scientific, J&J Settle Guidant Suit at The Wall Street Journal
05:40PM  Fossil Group shares drop after earnings miss at MarketWatch
05:17PM  Hospira Launches Inflectra, Remicade Biosimilar, in Europe - Analyst Blog Zacks
05:02PM  Boston Scientific settles $7.2B lawsuit brought by Johnson & Johnson for $600M at American City Business Journals
04:31PM  Boston Scientific settles J&J lawsuit over Guidant at MarketWatch
04:20PM  JNJ & BSX settle CNBC
04:01PM  The 4 Stocks That Buoyed the DJIA on Tuesday at 24/7 Wall St.
12:58PM  FMHR Final Trade: LOW, ICE, JNJ & CVLT CNBC
07:00AM  Mika Brzezinski goes Oprahor wants to be Sheryl Sandberg? at Fortune
Feb-16-15 08:36AM  If Pfizer's Right, Hospira Biosimilar Gold Rush Begins at Forbes
07:00AM  Corporate Tax Reform's Winners and Losers Morningstar
Feb-13-15 03:06PM  Brookdales 4Q14 results take a hit: Lower occupancy to blame Market Realist
11:18AM  Johnson & Johnson Faces Pressure From U.S. Patent Office Benzinga
07:50AM  Thursdays Notable Options Activity: Utilities From Hero to Zero Yahoo Finance Contributors
05:50AM  Companies pushing Ebola vaccines through trials won't let up, says Novavax CEO at American City Business Journals
Feb-12-15 06:37PM  Johnson & Johnson projects aim to spot who'll get a disease AP
04:00PM  For many of China's biotech brains-in-exile, it's time to come home Reuters
02:34PM  Johnson & Johnson Announces Patent and Trademark Office Action Related to REMICADE┬« PR Newswire
12:00PM  Gaithersburg's Novavax begins Phase 1 Ebola vaccine trials at American City Business Journals
Feb-11-15 06:25PM  Cramer: Why Tim Cook is Babe Ruth CNBC
02:42PM  Isis Pharma to Get $5M from Biogen - Analyst Blog Zacks
11:43AM  J&J drops bid to probe plaintiff solicitation in mesh cases Reuters
06:10AM  The Coming Boom In Brain Medicines at Forbes
Feb-09-15 01:36PM  Model Ophelia DeVore Stood Tall In Beauty Business at Investor's Business Daily
07:00AM  Johnson and Johnson, Inc. (JNJ): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Feb-06-15 02:15PM  Jennifer Hudson on New J&J Endorsement & Her Son at MarketWatch
Feb-05-15 05:27PM  Pfizer Grooms A Spinoff By Buying Hospira First Investor's Business Daily
11:00AM  Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary Zacks
Feb-04-15 05:08PM  [video] Jennifer Hudson Discusses Bobbi Kristina, Fame at MarketWatch
04:08PM  Strong dollar won't hurt these stocks at
07:00AM  Obama Pushes to Overhaul Silly, Counterproductive U.S. Corporate Tax System Morningstar
Feb-03-15 02:57PM  Americans lose interest in hiking corporate taxes Yahoo Finance
02:09PM  Mallinckrodt's Mixed Q1 Stokes Analyst Worries at Investor's Business Daily
11:12AM  Data Snapshot: VC-Backed BioPharma M&A 2014 at Forbes
06:49AM  J&J Sarcoma Drug Gets Priority Review at The Wall Street Journal
Feb-02-15 06:00PM  Cramer: As January goes, so doesn't go February? CNBC
05:50PM  Will Mallinckrodt (MNK) Disappoint Q1 Earnings Estimates? - Analyst Blog Zacks
12:22PM  Offshore corporate cash piles at risk from Obama tax plan at
Jan-30-15 05:55PM  Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog Zacks
04:50PM  Another absolutely wild day on Wall Street Yahoo Finance Contributors
11:39AM  Valeant Agrees To Buy Dendreon's Provenge at Investor's Business Daily
10:04AM  AbbVie reports better-than-expected 4Q on Humira sales AP
Jan-29-15 12:43PM  Novartis and J&J back UK biotech working on 30-minute STD test at Financial Times
11:29AM  FDA expands use of Imbruvica to treat rare form of cancer Reuters
07:06AM  Reputation Management With Digital And Social Media at Forbes
Jan-28-15 03:31PM  AmerisourceBergen's Revenue Growth May Slow Further at Investor's Business Daily
11:32AM  The most important thing to look for in Amazons earnings at MarketWatch
Jan-27-15 05:29PM  US company outlooks worry investors, sending stocks lower AP
04:50PM  US STOCKS-Wall St falls 1 pct on earnings; Apple rallies late Reuters
04:20PM  US STOCKS-Wall St ends down 1 pct on Caterpillar, Microsoft earnings Reuters
02:55PM  Zosano Pharma raises $50M after IPO hits target at American City Business Journals
08:00AM  Depression Drug That Works In One Day Passes Key Test at Forbes
Jan-26-15 04:45PM  CytRx Candidate Encourages in Soft Tissue Sarcoma Study - Analyst Blog Zacks
04:06PM  J&J Snack Foods posts 1Q profit AP
01:15PM  Jim Cramer Answers Twitter (TWTR) Questions on Johnson & Johnson, Alcoa, Mobileye, and Facebook at TheStreet
10:50AM  AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog Zacks
10:06AM  Pharmaceutical industry regulations Market Realist
09:30AM  The Zacks Analyst Blog Highlights: American Express, IBM, Johnson & Johnson, UnitedHealth Group and Travelers - Press Releases Zacks
Jan-23-15 05:20PM  Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog Zacks
04:55PM  Stocks mostly fall, curbing first weekly advance in 4 at CNBC
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women's health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON'S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusChief Scientific OfficerFeb 09Option Exercise0.0029,073064,647Feb 11 08:16 PM
Caruso Dominic JVP, Finance; CFOFeb 09Option Exercise0.0031,5370101,324Feb 11 08:16 PM
Fasolo PeterVP, Global Human ResourcesFeb 09Option Exercise0.0020,935042,109Feb 11 08:16 PM
Gorsky AlexChairman, CEOFeb 09Option Exercise0.0042,1120130,173Feb 11 08:17 PM
COSGROVE STEPHEN JCorporate ControllerJan 16Option Exercise0.0011,1080101,402Jan 21 05:48 PM
Ullmann Michael HVP, General CounselJan 16Option Exercise0.008,949075,628Jan 21 05:48 PM
Caruso Dominic JVP, Finance; CFOJan 16Option Exercise0.0012,615074,216Jan 21 05:48 PM
Gorsky AlexChairman, CEOJan 16Option Exercise0.0016,845094,425Jan 21 05:48 PM
Stoffels PaulusChief Scientific OfficerJan 16Option Exercise0.0011,629039,539Jan 21 05:48 PM
Fasolo PeterVP, Global Human ResourcesJan 16Option Exercise0.008,374024,336Jan 21 05:48 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,689031,210Dec 19 04:37 PM
JOHNSON & JOHNSON10% OwnerNov 12Buy18.0040,000720,0003,077,005Nov 12 03:06 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Option Exercise66.182,490164,78892,784Nov 07 04:49 PM
COSGROVE STEPHEN JCorporate ControllerNov 05Sale108.552,490270,29390,294Nov 07 04:49 PM
CULLEN JAMESDirectorSep 10Sale104.122,446254,6721,489Sep 11 02:19 PM
Caruso Dominic JVP, Finance; CFOAug 21Option Exercise66.1830,0001,985,40091,600Aug 25 04:35 PM
Caruso Dominic JVP, Finance; CFOAug 21Sale104.3030,0003,129,06961,600Aug 25 04:35 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM
Fasolo PeterVP, Global Human ResourcesMar 14Sale93.156,824635,64015,647Mar 17 06:10 PM
Fasolo PeterVP, Global Human ResourcesMar 04Option Exercise62.6644,8612,811,19243,571Mar 05 06:18 PM